Evaluation of a guideline directed medical therapy titration program in patients with heart failure with reduced ejection fraction

Abstract

IntroductionHeart failure is associated with recurrent hospitalizations and high mortality. Guideline directed medical treatment (GDMT), including beta blockers (BBs), angiotensin converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs) and aldosterone antagonists (AAs) has shown to improve outcomes. Current guidelines recommend the use of these medication classes at maximally tolerated dosages. Despite the evidence, < 25% of patients with heart failure with reduced left ventricular ejection fraction (HFrEF) are on the appropriate medical regimen titrated to the target doses. As such, we sought to assess the utility of a focused GDMT clinic to reduce this gap.MethodsWe conducted a retrospective chart review through existing patient data in a single center teaching hospital of patients referred to a focused GDMT clinic primarily staffed with heart failure trained nurse specialists, physician assistants and cardiologists. Management guidelines were developed with protocols for the initiation and uptitration of all therapeutic agents considered as GDMT.Our primary objective was to determine whether enrollment into a dedicated nursing led guideline directed medical therapy clinic would increase the proportion of patients with heart failure with reduced ejection fraction on appropriate medications as well as medication dosages in patients, the percentage of patients on the following medications and percentage at target doses: Renin-Angiotensin-Aldosterone System Blockers, Evidence Based Beta Blockers, and Aldosterone Antagonists. Our secondary objective was to determine if there was any clinical benefit on objective measures including renal function, hospital admissions, mortality and implantable defibrillator shocks.ResultsBetween October 2015 and March 2017, 63 patients were identified by requisition forms, in which 61 were able to be identified based on legibility of identifying information. Mean duration of follow up was 264.44 ± 162.68 days over 7 ± 3.94 days. Mean ejection fraction was 21.8 ± 7.3%. New onset cardiomyopathies (diagnosed within 30 days) compiled 21% of the patient population while those with demonstrated cardiomyopathies (> 90 days) compiled 48% of the patient population. Patients with NYHA class III heart failure compiled 65% of the patient population.There was a statistically significant increase in the mean number of GDMT at any dose (2.31 ± 0.76 to 2.74 ± 0.66; p < 0.001) and mean number of GDMT at target doses (0.54 ± 0.79 to 1.52 ± 1.1; p < 0.001). Percentage of the population that were on no target doses at initial visit was 62% which was reduced to 18% after intervention.Clinical improvement was reflected in significant improvement in ejection fraction from 21.8 ± 7.8% to 36.2 ± 14.3% (p < 0.001). Increases in sodium and chloride were statistically small but significant. There a significant reduction in heart failure hospitalizations in comparison to a year prior to after the initial encounter in the clinic (p < 0.001).ConclusionThis pilot study showed that a nurse direc...

An Observation of Racial and Gender Disparities in Congestive Heart Failure Admissions Using the National Inpatient Sample

“…Despite the anticipated increase, our data shows the rates of hospitalizations for CHF have not increased and in fact, appeared to decrease over a six-year span. This may be attributed to improved outpatient management of heart failure, optimization of guideline-directed medical therapy, as well as the focus by CMS to decrease 30 readmissions [14]. Our data suggests, however, that this improvement in outpatient management and benefit from primary care may not be ubiquitous amongst the population.…”

Cardiac Device Therapy in Heart Failure: Between Guidelines and Current Practice. Where Are We?

“…dence-based doses, which was consistent with other studies. 14,15 The current study assessed different predictors for prescription of GDMT; neither age, gender, cardiovascular risk factors nor blood pressure can predict prescription of GDMT in HF, apart from higher pulse rate that increases prescription of -blockers. The main predictors reported in other studies for GDMT prescription were absence of chronic kidney diseases and presence of non-sustained VT, 13 while the main reported predictors for underutilization of GDMT in HF were older age group, frail patients with multiple comorbidities fearing from side effects of drugs, higher renal indices, hyperkalaemia, lower body weight and patient non-compliance; all contributed to under-prescription of GDMT.…”

Anemia of cardiorenal syndrome

“…Guideline-directed medical therapy (GDMT), such as bblockers, ACEIs, and ARBs, has improved the management and clinical outcomes of patients with HF and those with CKD over the past few decades. 65,66 However, the management of CRAS is complicated and lacks specific recommendations that take into account progressively deteriorating kidney function, different stages of HF, and the presence/absence of diabetes, hypertension, and other comorbidities. The clinical manifestation of CRAS is a combination of these factors and may require different approaches in individual patients as well as frequent medication changes that may deviate from GDMT.…”